These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 15492507)
1. The importance of genome architecture in cancer susceptibility: location, location, location. Reilly KM Cell Cycle; 2004 Nov; 3(11):1378-82. PubMed ID: 15492507 [TBL] [Abstract][Full Text] [Related]
2. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Reilly KM; Tuskan RG; Christy E; Loisel DA; Ledger J; Bronson RT; Smith CD; Tsang S; Munroe DJ; Jacks T Proc Natl Acad Sci U S A; 2004 Aug; 101(35):13008-13. PubMed ID: 15319471 [TBL] [Abstract][Full Text] [Related]
3. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308 [TBL] [Abstract][Full Text] [Related]
4. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Ki DH; He S; Rodig S; Look AT Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693 [TBL] [Abstract][Full Text] [Related]
6. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Hawes JJ; Tuskan RG; Reilly KM Neurogenetics; 2007 Apr; 8(2):121-30. PubMed ID: 17216419 [TBL] [Abstract][Full Text] [Related]
7. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256 [TBL] [Abstract][Full Text] [Related]
9. Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Hong C; Maunakea A; Jun P; Bollen AW; Hodgson JG; Goldenberg DD; Weiss WA; Costello JF Cancer Res; 2005 May; 65(9):3617-23. PubMed ID: 15867356 [TBL] [Abstract][Full Text] [Related]
10. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261 [TBL] [Abstract][Full Text] [Related]
11. X chromosome protects against bladder cancer in females via a Kaneko S; Li X Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692 [TBL] [Abstract][Full Text] [Related]
12. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma. Mahalingam M Adv Anat Pathol; 2017 Jan; 24(1):1-14. PubMed ID: 27941538 [TBL] [Abstract][Full Text] [Related]
13. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Reilly KM; Broman KW; Bronson RT; Tsang S; Loisel DA; Christy ES; Sun Z; Diehl J; Munroe DJ; Tuskan RG Cancer Res; 2006 Jan; 66(1):62-8. PubMed ID: 16397217 [TBL] [Abstract][Full Text] [Related]
14. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic changes in cancer. Iacobuzio-Donahue CA Annu Rev Pathol; 2009; 4():229-49. PubMed ID: 18840073 [TBL] [Abstract][Full Text] [Related]
16. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail. Moon H; Ju HL; Chung SI; Cho KJ; Eun JW; Nam SW; Han KH; Calvisi DF; Ro SW Gastroenterology; 2017 Nov; 153(5):1378-1391.e6. PubMed ID: 28734833 [TBL] [Abstract][Full Text] [Related]
17. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR J Clin Invest; 2007 Jul; 117(7):1893-901. PubMed ID: 17607363 [TBL] [Abstract][Full Text] [Related]
18. [p53: an important or most overvalued tumor gene?]. Schlegel U Laryngorhinootologie; 1994 Dec; 73(12):651-3. PubMed ID: 7840829 [TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. Heng HH; Bremer SW; Stevens JB; Ye KJ; Liu G; Ye CJ J Cell Physiol; 2009 Sep; 220(3):538-47. PubMed ID: 19441078 [TBL] [Abstract][Full Text] [Related]
20. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis. Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]